Serum Vitronectin and Related Molecules in Chronic Kidney Disease

Abstract

One in eight people are reported to have chronic kidney disease (CKD). The renal function slowly deteriorateswhen nephrons become impaired by inflammatory and fibrotic processes. In this study, the relationshipsbetween vitronectin (VTN), plasminogen activator inhibitor-1 (PAI-1) and growth factor translation ?1(TGF-?1) are studied in CKD to assess the role as predict about progression stages of diseases. 105 patientswith early stages (1 to 3) of CKD and 35-69 age matched healthy controls were included in the study.The VTN, PAI-1, TGF-Bate levels of all participants were examined by Enzyme linked immune sorbentassay, creatinine, and urea by enzymatic method . Early morning urine sample was collected to be used fordetermination albumin creatinine ratio in patient with early stages of CKD. The renal function tests weresignificantly elevated in CKD group compared with healthy controls. The serum concentration of VTNincrease in early stages(1-2) of CKD and decrease significantly with progression of disease (stage 3). SerumPAI-1 antigen level increased significantly. With the development of CKD, the effective role of TFG-?became more severe,the correlation among VTN, TGF-? and PAI-1 was positive.Conclusions: These results indicate that VTN is important indicator for predict of CKD progression andboth VTN, PAI-1 are connected to TGF-?’s active form and can be used as a prediction for progression ofCKD.